Citations

Clear

623 citation(s) found for "Torres, V".

Efficacy of Tadalafil in Men with Erectile Dysfunction Naïve to Phosphodiesterase 5 Inhibitor Therapy Compared with Prior Responders to Sildenafil Citrate
Broderick, Gregory A. , Donatucci, Craig F., Hatzichristou, Dimitrios , Torres, Luiz Otávio , Valiquette, Luc, Zhao, Yanli , Loughney, Kate, Sides, Gregory D., Ahuja, Sanjeev

Mayo Clinic

The Journal of Sexual Medicine | June 16, 2006 | Volume: 3 | Issue: 4 | Pages: 668-675

10.1111/j.1743-6109.2006.00273.x | PMID 16839323 Get It

ABSTRACT Introduction Tadalafil, an inhibitor of phosphodiesterase 5 (PDE5), is indicated for treatment of erectile dysfunction. Most tadalafil clinical trials excluded patients with unsuccessful prior treatment with sildenafil citrate (sildenafil). Aim This retrospective analysis of pooled data from 14 tadalafil clinical trials examines the effect of this exclusion by comparing efficacy results in 1,349 patients without prior sildenafil use (naïve, presumably a mixture of potential responders and nonresponders) with efficacy results in 1,440 patients previously responsive to sildenafil (prior responders). Main Outcome Measures Efficacy measures included the International Index of Erectile Function (IIEF) erectile function (EF) domain, overall satisfaction (OS), and intercourse satisfaction (IS) domain scores; Sexual Encounter Profile (SEP) diary questions 2 through 5 (SEP2 [successful penetration], SEP3 [successful intercourse], SEP4 (satisfaction with hardness of erection), and SEP5 [overall satisfaction with the sexual experience]); and a Global Assessment Question (GAQ1) (13/14 trials) about erection improvement. Efficacy was compared using analysis of covariance (IIEF and SEP) and logistic regression (GAQ1) models. Methods After a 4-week, treatment-free, run-in period, patients in 14 double-blind, placebo-controlled, parallel-group trials were treated with tadalafil 10 mg, tadalafil 20 mg, or placebo for 12 weeks (dosed as needed before sexual activity, no more than once daily). Results Tadalafil improved erectile function compared with placebo (P < 0.001) in naïve patients and sildenafil prior responders for all efficacy measures. For most efficacy outcomes, responses in the naïve group (probable mix of responders and nonresponders) were not statistically different from responses in the prior-responder group (P ≥ 0.10). Conclusions The similar responses of these two patient groups observed in this post hoc analysis suggest, but do not confirm, that exclusion of sildenafil nonresponders in previously reported tadalafil clinical trials may not have substantially affected efficacy outcomes. Tadalafil improved erectile function in patients naïve to PDE5 inhibitor therapy and in patients who previously responded to sildenafil therapy.
Laparoscopic Marsupialization of Symptomatic Polycystic Kidney Disease
Brown, James A. , Torres, Vicente E. , King, Bernard F., Segura, Joseph W., Torres, Vicente E

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 156 | Issue: 1 | Pages: 22-27

10.1016/s0022-5347(01)65927-5 Get It

[Ca 2+ ] i Reduction Increases Cellular Proliferation and Apoptosis in Vascular Smooth Muscle Cells
Kip, Sertac N., Ren, Qun , Harris, Peter C. , Somlo, Stefan , Torres, Vicente E. , Sieck, Gary C. , Qian, Qi , Hunter, Larry W. , Sieck, Gary , Harris, Peter C , Torres, Vicente E

Mayo Clinic

Circulation Research | March 25, 2005 | Volume: 96 | Issue: 8 | Pages: 873-880

10.1161/01.res.0000163278.68142.8a | PMID 15790956 Get It

Cardiovascular complications are the leading cause of morbidity and mortality in autosomal dominant polycystic kidney disease. Pkd2 + /− vascular smooth muscle cells (VSMCs) have an abnormal phenotype and defective intracellular Ca 2+ ([Ca 2+ ] i ) regulation. We examined cAMP content in vascular smooth muscles from Pkd2 + /− mice because cAMP is elevated in cystic renal epithelial cells. We found cAMP concentration was significantly increased in Pkd2 + /− vessels compared with wild-type vessels. Furthermore, reducing the wild-type VSMC [Ca 2+ ] i by Verapamil or BAPTA-AM significantly increased cellular cAMP concentration (mainly by phosphodiesterase [PDE] inhibition), the rate of VSMC proliferation (determined by direct cell counting, 3 H-incorporation, FACS analysis of cells entering S phase, and quantitative Western PCNA and ERK1/2 analyses), and the rate of apoptosis (by Hoechst staining, FACS analysis of the Annexin-V positive cells, and quantitative Western Bax, cytochrome c , and activated caspase 9 and 3 analyses). The low [Ca 2+ ] i induced VSMC proliferation was independent of cAMP/B-Raf signaling, while that of apoptosis was promoted by cAMP. In summary, Pkd2 + /− VSMCs have elevated cAMP levels. This elevation can also be induced by reducing [Ca 2+ ] i in wild-type VSMCs. The [Ca 2+ ] i reduction and cAMP accumulation can cause an increase in both cellular proliferation and apoptosis, resembling Pkd mutant phenotype.